mp.weixin.qq.com·· 5 hours agoScore73
Gilead Signs Definitive Agreement to Acquire Oral IL-23R Inhibitor HCXT-2001 for $1.275 Billion Upfront
In brief
Gilead has announced a definitive agreement to acquire an oral IL-23R inhibitor from PepStar Therapeutics Limited for an upfront payment of $1.275 billion. The lead asset, HCXT-2001, is currently in Phase 1 clinical trials.
Source: mp.weixin.qq.com · mp.weixin.qq.com